A study reported that the 2‐year overall survival (OS) (68.0%; 95% confidence interval [CI]: 42.1%–84.2%) in patients with AML with BCR::ABL1 who underwent allo‐HCT is better than that in those with MPAL with BCR::ABL1 (43.3%; 95% CI: 29.5%–56.3%) [9]. The gene discussed is ABL1; the disease is mixed phenotype acute leukemia.